Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
197.42B
Market cap197.42B
Price-Earnings ratio
13.54
Price-Earnings ratio13.54
Dividend yield
2.61%
Dividend yield2.61%
Average volume
29.36M
Average volume29.36M
High today
$48.02
High today$48.02
Low today
$42.94
Low today$42.94
Open price
$45.05
Open price$45.05
Volume
54.45M
Volume54.45M
52 Week high
$93.80
52 Week high$93.80
52 Week low
$42.94
52 Week low$42.94

NVO News

The Motley Fool 4h
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.

There's another fight brewing around GLP-1 drugs -- this time on the delivery side. The headline-grabbing battle in the GLP-1 space pits pharmaceutical giants...

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
TipRanks 6h
Novo Nordisk Earnings Call: Growth Engine Meets 2026 Reset

Novo Nordisk ((NVO)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and...

Cheddar 8h
Novo Nordisk Threatens Lawsuit Over Cheap Hims Copy of Wegovy Pill

Novo Nordisk is planning legal and regulatory action against telehealth provider Hims & Hers after they announced it would sell a lower cost weight-loss pill....

Novo Nordisk Threatens Lawsuit Over Cheap Hims Copy of Wegovy Pill

Analyst ratings

50%

of 34 ratings
Buy
50%
Hold
35.3%
Sell
14.7%

More NVO News

Nasdaq 8h
Hims & Hers Takes On Novo Nordisk: What We Know Right Now

Hims & Hers (NYSE: HIMS) introduced a new oral GLP-1 product this morning only weeks after Novo Nordisk's (NYSE: NVO) hit oral version of Wegovy hit the market....

Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Simply Wall St 9h
Hims And Hers Weight Loss Push Faces Novo Nordisk Legal Challenge

Hims & Hers Health launched a compounded oral semaglutide pill as a low cost alternative to a major weight loss drug. Novo Nordisk responded by accusing the co...

Hims And Hers Weight Loss Push Faces Novo Nordisk Legal Challenge
TipRanks 10h
Novo Nordisk Publishes 2025 Annual Report

An update from Novo Nordisk ( (NVO) ) is now available. On 4 February 2026, Novo Nordisk A/S published its annual report for the 2025 financial year, making th...

TipRanks 10h
Novo Nordisk Discloses Management Share Transfers Under Long-Term Incentive Plan

Novo Nordisk ( (NVO) ) has issued an update. On 4 February 2026, several senior figures at Novo Nordisk, including board member Liselotte Sofie Hyveled, Presid...

Benzinga 12h
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action

Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for...

Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
The Motley Fool 13h
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.

Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials. Novo Nordisk and Eli Lilly are the two leading companies in the GLP-1...

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.
TipRanks 13h
Eli Lilly Stock Falls on News Hims & Hers Is Selling a $49 Weight-Loss Pill

Eli Lilly’s (LLY) stock is down 6% on news that telehealth company Hims & Hers Health (HIMS) is selling a $49 weight-loss pill. Claim 50% Off TipRanks Premium U...

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.